Recap: Gossamer Bio Q3 Earnings
Portfolio Pulse from Benzinga Insights
Gossamer Bio (NASDAQ:GOSS) reported its Q3 earnings, beating estimated earnings by 19.23% with an EPS of $-0.21 versus an estimate of $-0.26. However, revenue was down $0 from the same period last year. Last quarter, the company also beat EPS estimates, which was followed by a 1.64% drop in the share price the next day.
November 09, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Gossamer Bio's Q3 earnings beat estimates, but revenue was flat compared to last year. Last quarter's earnings beat was followed by a 1.64% drop in share price.
Gossamer Bio's earnings beat is a positive signal, but the lack of revenue growth and the previous quarter's share price drop following an earnings beat suggest a mixed impact on the stock price. Investors may be concerned about the company's ability to translate earnings beats into revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100